The Cochlear™ Baha® 5 SuperPower Sound Processor is intended for treatment of patients who have conductive or mixed hearing loss as a result of certain medical conditions such as bilateral atresia and chronic supportive otitis media, and for those who have Single-Sided Deafness (SSD) caused by a congenital condition, surgery, trauma, or disease.

The Cochlear™ Baha® 5 SuperPower Sound Processor has the following indications for use:
• Patients of any age for use with the Baha Softband or headband. Patients aged 5 and older for use with the Baha auditory osseointegrated implant system.
· Patients who have a conductive or mixed hearing loss and can still benefit from sound amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 65 dB HL.
· Bilateral fitting is intended for patients who meet the criterion in both ears, with bilateral symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conduction thresholds are defined as less than a 10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz), or less than a 15 dB difference at individual frequencies.
· Patients who suffer from unilateral sensorineural deafness in one ear with normal hearing in the other ear (i.e. Single-Sided Deafness; SSD). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 dB HL.
• Baha for SSD is also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

Device Description

The Cochlear™ Baha® 5 SuperPower Sound Processor functions by combining the external sound processor with an abutment and a small titanium implant placed that is placed in the skull behind the ear through a simple surgical procedure. The sound processor transmits acoustic signals into electrical signals when then causes mechanical action in the transducer to transmit sound transcranially to the functioning auditory system. The Baha system combines an external sound processor, in this application the Cochlear™ Baha® 5 SuperPower Sound Processor, with an abutment and small titanium implant placed into the bone through a simple surgical procedure. The implant subsequently forms an osseointegrated bond with the surrounding bone, allowing transmission of high-quality sound directly to the inner ear, bypassing a damaged outer or middle ear. The Baha system provides an alternate pathway for patients who may not benefit from wearing an air-conduction hearing aid. The changes introduced in this 510(k) are specific to the sound processor, not the abutment/implant or magnet. These changes culminate as the next generation Baha sound processor that provides recipients with moderately severe hearing loss (up to 65dB SNHL) access to sound. The Cochlear™ Baha® 5 SuperPower Sound Processor includes a decoupling of the microphone/processor and the actuator unit to allow various wearing options. The wearing options allow the recipient to achieve maximum gain while minimizing the likelihood of feedback. The design has been modified to incorporate a new rechargeable lithium-ion battery pack which provides the power needed for recipients with up to 65dB SNHL measured by pure tone average bone-conduction hearing thresholds at 0.5, 1, 2, and 3 kHz. This change does not modify the intended functionality or fundamental operating principles of the implant/abutment system.

AI/ML Overview

The provided text describes the Cochlear™ Baha® 5 SuperPower Sound Processor and its substantial equivalence to predicate devices, but it does not contain information about acceptance criteria or a study that proves the device meets specific performance criteria in the format requested.

The document is a 510(k) premarket notification for a medical device (a hearing aid). In a 510(k) submission, the primary goal is to demonstrate "substantial equivalence" to a legally marketed predicate device, rather than proving performance against pre-defined acceptance criteria in the same way a de novo or PMA submission might.

Here's a breakdown of why the requested information cannot be fully extracted and what is available:

What the document does provide:

Device Name: Cochlear™ Baha® 5 SuperPower Sound Processor
Intended Use: Treatment of patients with conductive or mixed hearing loss, or Single-Sided Deafness (SSD).
Indications for Use: Detailed criteria for patient age, hearing thresholds (bone-conduction and air-conduction), and conditions for bilateral fitting or SSD. These essentially are the "acceptance criteria" for patient selection and device applicability, not performance criteria of the device itself.
Predicate Devices: Cordelle II Sound Processor (K150751) and Baha 5 Sound Processor (K142907).
Performance Data Mentioned: "Performance testing was conducted to compare the Cochlear™ Baha® 5 SuperPower Sound Processor with the predicate implant / abutment systems. Substantial equivalence to the predicate device was accomplished through environmental testing, reliability and durability testing, electrical interface testing, and functional and performance testing. The results demonstrated the Cochlear™ Baha® 5 SuperPower Sound Processor is functionally equivalent to the predicate devices."

Why the requested table and study details cannot be filled from the provided text:

A table of acceptance criteria and the reported device performance:
- The document lists indications for use, which are criteria for patient eligibility and how the device should be used, not performance metrics of the device itself (e.g., sound quality, gain, battery life, speech understanding scores). There are no specific numerical performance targets (e.g., "device shall achieve a 10 dB improvement in speech recognition score") and no corresponding measured performance values.
- The "performance testing" mentioned is general and aimed at demonstrating "functional equivalence" to predicate devices, but the specific metrics, acceptance thresholds, and measured results are not provided.
Sample size used for the test set and the data provenance: Not mentioned.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable or mentioned. The "performance testing" described is likely engineering/technical testing rather than human-expert-based clinical evaluation for establishing ground truth as one might see in an AI/diagnostic device.
Adjudication method for the test set: Not applicable or mentioned.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This is not an AI/diagnostic device that relies on human readers interpreting outputs. It's a hearing aid.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable in the context of an AI algorithm, as this is a physical medical device. The device's "standalone" performance is its function as a hearing aid, which is what the general "functional and performance testing" refers to, but without specifics.
The type of ground truth used: For the purposes of a 510(k) for a hearing aid, "ground truth" would relate to the objective physical and acoustical performance characteristics (e.g., output sound pressure level, frequency response, distortion, battery drain) and potentially clinical outcomes in human subjects (e.g., audiological tests). The document states "Substantial equivalence to the predicate device was accomplished through environmental testing, reliability and durability testing, electrical interface testing, and functional and performance testing," implying objective physical measurements were the "ground truth" for these engineering tests.
The sample size for the training set: Not applicable. This is not a machine learning/AI device that requires a training set.
How the ground truth for the training set was established: Not applicable.

Summary Table based on available information:

Acceptance Criteria (from Indications for Use)	Reported Device Performance (Implied by Substantial Equivalence)
Patient Age: ≥ 5 years (for implant system); any age (for Softband/headband)	The device is deemed safe and effective for its intended use, which includes these age groups, through demonstrated substantial equivalence to predicate devices.
Hearing Loss Type: Conductive or mixed hearing loss	The device is functionally equivalent to predicate devices for treating these types of hearing loss.
Bone-Conduction Threshold (Conductive/Mixed): PTA ≤ 65 dB HL (at 0.5, 1, 2, 3 kHz)	The device provides the necessary amplification and sound transmission for patients meeting this criterion, as demonstrated by "functional and performance testing" and comparison to predicate devices, which also serve this patient population. The device is designed to provide "maximum gain" for recipients with up to 65dB SNHL.
Bilateral Fitting Criteria: Symmetric moderate to severe conductive or mixed hearing loss (average difference < 10 dB between ears, or < 15 dB at individual frequencies at 0.5, 1, 2, 3 kHz)	The device's design supports bilateral fitting for patients meeting these criteria, consistent with the predicate devices.
Single-Sided Deafness (SSD): Unilateral sensorineural deafness with normal hearing in the other ear (PTA air-conduction ≤ 20 dB HL at 0.5, 1, 2, 3 kHz)	The device is functionally equivalent to predicate devices for treating SSD according to this definition.
Alternative to AC CROS: Indicated for AC CROS but cannot/will not use it	The device serves as an effective alternative for these patients, consistent with predicate devices.
Environmental Performance: (Not explicitly stated as criterion, but implied by testing)	Passed environmental testing.
Reliability and Durability: (Not explicitly stated as criterion, but implied by testing)	Demonstrated reliability and durability.
Electrical Interface Performance: (Not explicitly stated as criterion, but implied by testing)	Passed electrical interface testing.

Regarding the Study "Proving Acceptance":

The document states:
"Performance testing was conducted to compare the Cochlear™ Baha® 5 SuperPower Sound Processor with the predicate implant / abutment systems. Substantial equivalence to the predicate device was accomplished through environmental testing, reliability and durability testing, electrical interface testing, and functional and performance testing. The results demonstrated the Cochlear™ Baha® 5 SuperPower Sound Processor is functionally equivalent to the predicate devices."

This statement is the description of the "study" (or rather, a series of tests) performed to demonstrate that the device meets the regulatory standard of substantial equivalence. However, it lacks all the specifics requested in your prompt (sample size, experts, ground truth details, etc.) because these are typically not detailed in the summary document for a 510(k) or are not relevant for this type of device and regulatory pathway. The "acceptance criteria" for these tests would have been that the new device's performance fell within an acceptable range compared to the predicate device for each tested parameter, or met established industry standards.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines representing hair or clothing.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

Cochlear Americas Mr. Tristan Manus Regulatory Affairs Specialist 13059 E. Peakview Ave. Centennial. CO 80111

Re: K153245

Trade/Device Name: Baha 5 Super Power Sound Processor Regulation Number: 21 CFR 874.3300 Regulation Name: Hearing Aid Regulatory Class: Class II Product Code: LXB Dated: January 29, 2016 Received: February 1, 2016

Dear Mr. Manus:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Kesia Alexander

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

{2}------------------------------------------------

4. Indications for Use Statement

510(k) Number (if known): K153245

Device Name: Cochlear™ Baha® 5 SuperPower Sound Processor

Indications for Use:

The Cochlear™ Baha® 5 SuperPower Sound Processor is intended for the following patients and indications for use:

Patients aged 5 and older o
Patients who have a conductive or mixed hearing loss and can still benefit from sound ● amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3kHz) should be better than or equal to 65 dB HL for use with the Baha 5 SuperPower Sound Processor.
Bilateral fitting is intended for patients who meet the above criterion in both ears, with o bilaterally symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conduction thresholds are defined as less than a 10 dB average difference between ears (measure at 0.5, 1, 2, and 3 kHz), or less than a 15 dB difference at individual frequencies.
Patients who suffer from unilateral sensorineural deafness in one was with normal ● hearing in the other ear (i.e. Single-sided deadness: SSD™). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measure at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 dB HL.
Baha for SSD is also indicated for any patient who is indicated for an air-conduction ● contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

Prescription Use	X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 801 Subpart C)

(PLEASE FO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

{3}------------------------------------------------

K153245

510(K) Summary

A. Submitter Information Submitted by:

On behalf of the manufacturer

Contact:

B. Date Prepared

C. Device Class D. Device Name

Trade/Proprietary Name:

Common/Usual Name: Classification Name:

Classification Panel: Product Code: 510(k):

E. Predicate Device

(Primary) Trade/Proprietary Name: Common/Usual Name: Classification Name:

Classification Panel Product Code: 510(k):

(Secondarv) Trade/Proprietary Name: Common/Usual Name: Classification Name:

Classification Panel:

Cochlear Americas 13059 East Peakview Ave. Centennial, CO 80111

Cochlear Bone Anchored Solutions AB Konstruktionsvagen 14 SE-435 33 Molnlycke Sweden (Establishment Number 9616024)

Tristan Manus Regulatory Affairs Specialist II Cochlear Americas tmanus@cochlear.com (303) 264-2149 (o) (303) 524-6825 (f)

November 6th 2015

II

Cochlear™ Baha® 5 SuperPower Sound Processor Hearing Aid (Bone Conduction) Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear, Nose, and Throat LXB K153245

Cordelle II Sound Processor Auditory Osseointegrated Implant Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear, Nose, and Throat LXB K150751

Baha 5 Sound Processor Auditory Osseointegrated Implant Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear, Nose, and Throat

{4}------------------------------------------------

Product Code: 510(k):

LXB K142907

F. Purpose of Submission

This submission is adding the Cochlear™ Baha® 5 SuperPower Sound Processor to the series of processors offered by Cochlear Bone Anchored Solutions (BAS). The Cochlear™ Baha® 5 SuperPower Sound Processor functions by combining the external sound processor with an abutment and a small titanium implant placed that is placed in the skull behind the ear through a simple surgical procedure. The sound processor transmits acoustic signals into electrical signals when then causes mechanical action in the transducer to transmit sound transcranially to the functioning auditory system.

G. Device Description

The technology base for the Baha implant was originally derived from the 1952 discovery by Dr. Per-Ingvar Branemark that titanium was biocompatible with bone, leading to the term "osseointegration"". The Branemark System, as it would later be known, formed the basis for the rapid development and widespread implementation of root form endosseous dental implants, now safely and effectively used by many hundreds of thousands of people worldwide. Root form dental implants share many characteristics with the Baha implant component including material, conformation, and surgical implantation procedures. Unlike hearing aids, the Baha hearing system utilizes a natural bone conduction pathway to send sound directly to a cochlea with residual functionality. The Baha system combines an external sound processor, in this application the Cochlear™ Baha® 5 SuperPower Sound Processor, with an abutment and small titanium implant placed into the bone through a simple surgical procedure. The implant subsequently forms an osseointegrated bond with the surrounding bone, allowing transmission of high-quality sound directly to the inner ear, bypassing a damaged outer or middle ear. The Baha system provides an alternate pathway for patients who may not benefit from wearing an air-conduction hearing aid. The changes introduced in this 510(k) are specific to the sound processor, not the abutment/implant or magnet. These changes culminate as the next generation Baha sound processor that provides recipients with moderately severe hearing loss (up to 65dB SNHL) access to sound. The Cochlear™ Baha® 5 SuperPower Sound Processor includes a decoupling of the microphone/processor and the actuator unit to allow various wearing options. The wearing options allow the recipient to achieve maximum gain while minimizing the likelihood of feedback. The design has been modified to incorporate a new rechargeable lithium-ion battery pack which provides the power needed for recipients with up to 65dB SNHL measured by pure tone average bone-conduction hearing thresholds at 0.5, 1, 2, and 3 kHz. This change does not modify the intended functionality or fundamental operating principles of the implant/abutment system.

H. Intended Use

I. Indications for Use

The Cochlear™ Baha® 5 SuperPower Sound Processor has the following indications for use:

• Patients of any age for use with the Baha Softband or headband. Patients aged 5 and older for use with the Baha auditory osseointegrated implant system.

{5}------------------------------------------------

· Patients who have a conductive or mixed hearing loss and can still benefit from sound amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 65 dB HL.

· Bilateral fitting is intended for patients who meet the criterion in both ears, with bilateral symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conduction thresholds are defined as less than a 10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz), or less than a 15 dB difference at individual frequencies.

· Patients who suffer from unilateral sensorineural deafness in one ear with normal hearing in the other ear (i.e. Single-Sided Deafness; SSD). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 dB HL.

• Baha for SSD is also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

J. Technological Characteristics

The Cochlear™ Baha® 5 SuperPower Sound Processor has the same intended use, the same mechanical design, the same functional characteristics, the same fundamental operating principles, and is made of biocompatible materials as the predicate devices.

K. Materials

The Cochlear™ Baha® 5 SuperPower Sound Processor is made of medical grade plastics and metals that have been shown to be biocompatible and safe for human use.

L. Performance Data

Performance testing was conducted to compare the Cochlear™ Baha® 5 SuperPower Sound Processor with the predicate implant / abutment systems. Substantial equivalence to the predicate device was accomplished through environmental testing, reliability and durability testing, electrical interface testing, and functional and performance testing. The results demonstrated the Cochlear™ Baha® 5 SuperPower Sound Processor is functionally equivalent to the predicate devices.

M. Conclusion

Based on the indications for use, technological characteristics, and substantial equivalence comparison to the predicate device, the Cochlear™ Baha® 5 SuperPower Sound Processor has been shown to be safe and effective for its intended use.

Regulation Number and Section

§ 874.3302 Bone-conduction hearing aid.

(a)
Identification. A bone-conduction hearing aid is a wearable sound-amplifying device intended to compensate for impaired hearing and that conducts sound to the inner ear through the skull. The non-implantable components of a bone-conduction hearing aid, such as the external sound processor, are subject to the requirements in § 801.422 of this chapter.(b)
Classification. Class II.